Filing Flows › Niagen Bioscience (NAGE) › Q3 2026 › vs Q3 2025
Niagen Bioscience (NAGE) Q3 2026 vs Q3 2025 (year over year)
Niagen Bioscience's revenue fell $6.8M (-20%) from $34.0M in Q3 2025 to $27.2M in Q3 2026. The biggest changes: Ingredients segment −$3.4M (-47%); Consumer Products segment −$2.7M (-10%).
Niagen Bioscience, Q3 2026: revenue $27.2M (-20% year over year), operating margin -5.8%, net loss $1.2M, operating cash flow $2.6M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Consumer Products segment | $23.3M | $26.0M | −$2.7M | -10% |
| Ingredients segment | $3.8M | $7.2M | −$3.4M | -47% |
| Revenue | $27.2M | $34.0M | −$6.8M | -20% |
| Other income, net | $414K | $564K | −$150K | -27% |
| Net loss | $1.2M | −$4.6M | $5.8M | — |
| Costs & expenses | $28.8M | $34.5M | −$5.8M | -17% |
| Operating costs | $28.8M | $29.8M | −$971K | -3% |
| Cost of revenue | $10.1M | $12.1M | −$2.0M | -16% |
| Research & development | $1.8M | $1.8M | $1K | +0.1% |
| Sales & marketing | $8.7M | $8.8M | −$55K | -0.6% |
| General & admin | $8.2M | $7.1M | $1.1M | +15% |
| Operating cash sources | $3.8M | −$886K | $4.7M | — |
| Depreciation & amortization | $290K | $195K | $95K | +49% |
| Share-based compensation | $1.5M | $1.8M | −$234K | -13% |
| Working capital & other | $2.0M | −$2.8M | $4.8M | — |
| Net loss absorbed | $1.2M | −$4.6M | $5.8M | — |
| Operating cash flow | $2.6M | $3.7M | −$1.1M | -29% |
Questions
How much did Niagen Bioscience's revenue grow year over year in Q3 2026?
Niagen Bioscience's revenue fell $6.8M (-20%) from $34.0M in Q3 2025 to $27.2M in Q3 2026.
What drove Niagen Bioscience's revenue change in Q3 2026?
Ingredients segment −$3.4M (-47%); Consumer Products segment −$2.7M (-10%).